References in periodicals archive ?
The results merit further studies to evaluate the potential therapeutic substitution of, or combination with L-T4 for the treatment of hypothyroidism.
As a result, current guidelines recommend that L-T4 is taken in a fasting state at least 30 minutes before breakfast [6-8].
Secondly, it is not always reliable to follow medical advice, especially for drug therapy [9]; this is especially relevant for L-T4 therapy as a significant number of patients have problems in postponing their breakfast by 30-60 minutes to ensure that they take L-T4 in the fasting state [10].
The L-T4 dose was reduced to 50 [micro]g/day and TFT results were maintained within reference intervals.
TSH lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients.
Therefore, the bone marrow-absorbed dose after treatment with RAI would be expected to be lower for patients given rhTSH, which is protective for hypothyroidism and additionally may reduce the half-life of RAI, than for patients subjected to L-T4 withdrawal (12-14).
Tightening of potency specifications will alleviate some, but not all, of the measured variability among L-T4 products, and it does nothing to address the flawed method by which FDA determines bioequivalence of the drugs.
As of January 2007, four branded oral L-T4 products were available in the United States: levothyroxine sodium (Unithroid, Levoxyl, Synthroid and Levothroid).
Bioavailability of L-T4 was reduced by 40% regardless of whether subjects took the drug shortly before or immediately after the meal.
As of January 2005, seven branded orally administered L-T4 products have been approved by the U.
This is a clinically significant finding, because it is well established that even small changes in L-T4 bioavailability can have a profound impact upon the success of oral replacement therapy.
Several were already on L-T4 [levothyroxine] therapy because of manifest hypothyroidism.